Plain-English translation of NCT06940154 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called rademikibart to see if it helps people recover from sudden, severe flare-ups of chronic obstructive pulmonary disease (COPD). You would receive this medication along with the standard treatment doctors normally give during a flare-up. The trial will compare people who get the new medication to those who get standard treatment alone to see which works better.
When COPD flare-ups happen, they can be serious and hard to control with standard treatments alone. Researchers believe this new medication may help reduce inflammation and help people recover more quickly, especially those whose bodies show signs of a specific type of inflammation.
If you join this trial during a COPD flare-up, you'll be randomly assigned to either receive the new medication along with your standard treatment, or to receive standard treatment with a placebo (inactive pill). You'll participate in an urgent healthcare setting where doctors can monitor your recovery. The study will follow your progress to see how well the treatment works and whether it's safe.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States